- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on mCRPC
Total 112 results
-
Impact Therapeutics, Inc.Not yet recruitingmCRPCAustralia, United States, China
-
AstraZenecaCompleted
-
Propella TherapeuticsRecruitingProstate Cancer | mCRPC | mCSPCUnited States
-
PfizerCompletedMetastatic Castration Resistant Prostate Cancer (mCRPC) | Metastatic Castration Sensitive Prostate Cancer (mCSPC)Finland
-
Istituto Scientifico Romagnolo per lo Studio e...RecruitingProstate-specific Membrane Antigen | mCRPC or Advanced/Metastatic Solid TumorsItaly
-
PfizerAstellas Pharma IncActive, not recruitingmCRPCChina, Finland, Spain, United States, Hungary, Israel, Belgium, Korea, Republic of, France, Canada, Czechia, Australia, Japan, Brazil, Germany, Argentina, New Zealand, United Kingdom, Norway, South Africa, Poland, Portugal, Chile, Italy, Pe... and more
-
Zenith EpigeneticsEnrolling by invitation
-
Promontory Therapeutics Inc.Active, not recruitingUrogenital Neoplasms | Neoplasms by Site | Genital Neoplasms, Male | Prostatic Neoplasms | Advanced Solid Tumors | mCRPC | Metastatic Castrate-resistant Prostate Cancer | CRPC | PT-112United States, France
-
Dr.Laurent MineurMerck Serono International SA; BESPIM, CHU Nîmes (data analysis)Unknown
-
AmgenCompleted
-
BayerCompletedMetastatic Castration-resistant Prostate Cancer (mCRPC)United States
-
BayerCompletedMetastatic Castration Resistant Prostate Cancer (mCRPC)United States
-
Jiangsu HengRui Medicine Co., Ltd.CompletedMetastatic Castration-resistant Prostate Cancer (mCRPC)China
-
Suzhou Kintor Pharmaceutical Inc,CompletedMetastatic Castrate Resistant Prostate Cancer (mCRPC)United States
-
Memorial Sloan Kettering Cancer CenterProgenics Pharmaceuticals, Inc.CompletedProstate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)United States
-
FutureChemRecruitingMetastatic Castration-resistant Prostate Cancer, mCRPCKorea, Republic of
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC)Korea, Republic of, United States, Spain, France, Belgium, China, Taiwan, United Kingdom, Australia, Czechia, Hungary, Poland, Russian Federation
-
University of Texas Southwestern Medical CenterCompletedmCRPC | Metastatic Castrate-resistant Prostate CancerUnited States
-
Constellation PharmaceuticalsActive, not recruitingMetastatic Castration Resistant Prostate Cancer (mCRPC)United States
-
GenesisCare USADendreonCompletedCastrate Refractory Metastatic Prostate Cancer (mCRPC)United States
-
Avionco LLCCompletedMetastatic Castration-Resistant Prostate Cancer (mCRPC)Russian Federation
-
UNC Lineberger Comprehensive Cancer CenterWithdrawnMetastatic Castration Resistant Prostate Cancer (mCRPC)United States
-
BeiGeneTerminatedMetastatic Castration-Resistant Prostate Cancer (mCRPC) | Homologous Recombination Deficiency (HRD)United States, Australia, Puerto Rico, Spain
-
Hinova Pharmaceuticals Inc.Recruiting
-
The First Affiliated Hospital of Xiamen UniversityRecruitingMetastatic Castration-resistant Prostate Cancer, mCRPCChina
-
University of PennsylvaniaProstate Cancer FoundationRecruiting
-
Peter MacCallum Cancer Centre, AustraliaRecruitingProstate Cancer | Metastatic Castration-resistant Prostate Cancer | mCRPCAustralia
-
British Columbia Cancer AgencyRecruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC)Canada
-
AstraZenecaCompletedProstate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)United States
-
Advanced Accelerator ApplicationsNo longer availableMetastatic Castration-resistant Prostate Cancer (mCRPC)
-
Cellbion Co., Ltd.Recruiting
-
SL VAXiGENRecruitingMetastatic Castration-resistant Prostate Cancer (mCRPC)Korea, Republic of
-
Yantai LNC Biotechnology Singapore PTE. LTD.Not yet recruitingMetastatic Castration-resistant Prostate Cancer, mCRPC
-
Merck Sharp & Dohme LLCOrion Corporation, Orion PharmaRecruitingProstatic Neoplasms | Metastatic Castration-resistant Prostate Cancer (mCRPC)United States, Puerto Rico, Israel, Australia, Korea, Republic of, Taiwan, China, Costa Rica, Guatemala, Spain
-
Inmune Bio, Inc.RecruitingCancer | Metastatic Castration-resistant Prostate Cancer | mCRPCUnited States
-
University of OklahomaDendreonRecruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC)United States
-
Peter MacCallum Cancer Centre, AustraliaRecruitingMetastatic Castration-resistant Prostate Cancer | mCRPCAustralia
-
Peter MacCallum Cancer Centre, AustraliaRecruitingMetastatic Castration Resistant Prostate Cancer (mCRPC)Australia
-
BayerActive, not recruitingMetastatic Castration Resistant Prostate Cancer (mCRPC)United States, United Kingdom, Finland
-
Novartis PharmaceuticalsActive, not recruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC)China
-
AstraZenecaCompletedMetastatic Castrate-Resistant Prostate Cancer (mCRPC), | Efficacy, | Safety and Tolerability, | Pharmacokinetics, | Pharmacodynamics, | Tumour Response.United Kingdom, United States
-
MediLink Therapeutics (Suzhou) Co., Ltd.RecruitingMetastatic Castration-resistant Prostate Cancer (mCRPC)China
-
DendreonNot yet recruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC)
-
Novartis PharmaceuticalsRecruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC)Spain, France
-
BayerRecruitingMetastatic Castrate Resistant Prostate Cancer (mCRPC)Hong Kong, Spain, Taiwan, Australia, Turkey, France, Germany, Hungary, United Kingdom, Singapore, Korea, Republic of, Czechia, Italy, Finland, Israel, Austria, Lithuania, Poland, Russian Federation
-
Peter MacCallum Cancer Centre, AustraliaSuspendedPidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer (REPAIR)Metastatic Castration Resistant Prostate Cancer (mCRPC)Australia
-
Istituto Scientifico Romagnolo per lo Studio e...TerminatedMetastatic Castration Resistant Prostate Cancer (mCRPC)Italy
-
Novartis PharmaceuticalsRecruitingMetastatic Castration-resistant Prostate Cancer (mCRPC)France
-
Novartis PharmaceuticalsRecruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC)China
-
Karolinska InstitutetThe Swedish Research Council; AstraZeneca; Janssen Pharmaceutica N.V., Belgium; Kom Op Tegen Kanker and other collaboratorsRecruitingMetastatic Castration-resistant Prostate Cancer (mCRPC) | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Sweden, Belgium, Switzerland, Norway